Compare TG Therapeutics Inc (TGTX) vs Clear Secure Inc (YOU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Clear Secure Inc — how do they compare? TG Therapeutics Inc trades at $54 (market cap $8.26B), while Clear Secure Inc trades at $57.03 (market cap $5.76B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and Clear Secure Inc pays a 1.05% dividend while TG Therapeutics Inc pays none. Which is the better fit depends on your goals.
| TGTX | YOU | |
|---|---|---|
Market Cap | $8.26B | $5.76B |
Sector | Health | Technology |
52-Week High | $59.06 | $62.36 |
52-Week Low | $26.39 | $28.84 |
Enterprise Value | $8.50B | $5.07B |
Dividend Yield | — | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $53.96, down 1.6% today, with a bullish technical signal and strong profitability metrics including a 65.95% net income margin. Recent news highlights clinical progress, including a Phase 2 trial for Briumvi in schizophrenia (Zacks Investment Research, 2026-07-07) and positive Phase 1 data for subcutaneous Briumvi (GlobeNewsWire, 2026-06-03). However, earnings misses in Q4 2025 and Q1 2026 and a shareholder investigation (PRNewsWire, 2026-07-21) introduce volatility.
The outlook is mixed: analyst consensus is strongly bullish (84.6% buy ratings) with a $48.50 price target, but near-term risks from legal scrutiny and earnings inconsistency warrant caution. Upside hinges on successful drug trials and sales growth, while downside risks include legal outcomes and competitive pressures in the biotech sector.
Clear Secure (YOU) trades at $57.18, up 2.05% with a bullish technical outlook. The stock shows strong profitability with 65.48% gross margins and 81.15% ROE, though valuation multiples appear elevated with a P/E of 45.74. Recent earnings beat expectations in Q1 2026 with $0.38 EPS versus $0.35 expected. The company continues expanding airport partnerships and launched AWS integration for contact center verification in June 2026.
Growth prospects remain positive with revenue projected to reach $942 million in 2026, but high valuation multiples and mixed analyst ratings (44% Buy, 44% Hold) suggest cautious optimism. Key risks include execution of expansion plans and competitive pressures in identity verification markets. The consensus price target of $56.67 offers limited upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Clear Secure Inc
Clear Secure operates a secure identity platform that uses biometrics—specifically eyes, face, and fingerprints—to automate and expedite identity verification. While its most visible application is the CLEAR Plus airport subscription service, the company functions as a broad-based identity layer for travel, healthcare, and digital services, aiming to replace physical IDs with a secure, biometric link.
Read more on YOU →
